高级或复发性原发性黏液性卵巢癌通常无法治愈，并且在接受标准化疗时进展无法避免，总体生存期很短。对于这种疾病的女性急需新的治疗方法。两位患有高级或复发性原发性黏液性卵巢癌的患者接受了二次细胞减数手术（CRS）和腹腔热疗化疗（HIPEC）。手术后没有额外的化疗治疗。两位患者都获得了完全和持久的反应，并在分别进行CRS和HIPEC后的21和27个月内没有复发的证据。二次性CRS和HIPEC代表着一种潜在的治疗选择，适用于患有复发性原发性黏液性卵巢癌的女性。版权所有©2023年美国妇产科医生协会。 Wolters Kluwer Health公司出版。保留所有权利。

Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.